A new hope for targeted therapy of ischemia-reperfusion injury: E2F2, an important transcription factor in H/R process

Abstract

Abstract Background At present, there is still no effective treatment for ischemia-reperfusion injury (IRI), and gene targeted drug therapy is a new idea. In this study, the differential expression of multiple genes and transcription factors during HUVECs ischemia-reperfusion was analyzed by bioinformatics methods, and the target genes were predicted and verified by q-PCR. Therefore, the mechanism by which E2F2 may participate in the development of ischemia-reperfusion injury by regulating differentiation factor 1 (ID1) was explored.Results The mRNA expression profile dataset GSE193047 was acquired from the GEO database. Heat map and volcano plot showed that a total of 270 genes were differentially expressed, of which 150 genes were up-regulated and 120 genes were down-regulated. The GSEA of transcription factor indicated the significant enrichment of E2F2. Then the online prediction websites CHIP BASE and CISTROME were used to predict the target genes of E2F2. Considering the low expression of E2F2 in dataset GSE193047, down-regulated target genes of E2F2 in this dataset were identified. By constructing the target gene network, it was found that the target gene ID1 may be regulated by E2F2, and the significant differences were verified by q-PCR.Conclusions The constructed E2F2-target gene regulatory network was analyzed by bioinformatics methods, which showed that E2F2 may participate in the development of ischemia-reperfusion injury by regulating ID1. This study revealed a new mechanism involved in IRI, which may serve as a potential predictive biomarker and therapeutic target. Further study is needed to investigate the role of E2F2/ ID1 pathway in the occurrence and development of ischemia-reperfusion injury.